Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia

Thrombosis and Haemostasis
Virginia AlbiñanaLuisa M Botella

Abstract

The β-blocker propranolol, originally designed for cardiological indications (angina, cardiac arrhythmias and high blood pressure), is nowadays, considered the most efficient drug for the treatment in infantile haemangiomas (IH), a vascular tumour that affects 5-10% of all infants. However, its potential therapeutic benefits in other vascular anomalies remain to be explored. In the present work we have assessed the impact of propranolol in endothelial cell cultures to test if this drug could be used in the vascular disease hereditary haemorrhagic telangiectasia (HHT). This rare disease is the result of abnormal angiogenesis with epistaxis, mucocutaneous and gastrointestinal telangiectases, as well as arteriovenous malformations in several organs, as clinical manifestations. Mutations in Endoglin (ENG) and ACVLR1 (ALK1) genes, lead to HHT1 and HHT2, respectively. Endoglin and ALK1 are involved in the TGF-β1 signalling pathway and play a critical role for the proper development of the blood vessels. As HHT is due to a deregulation of key angiogenic factors, inhibitors of angiogenesis have been used to normalise the nasal vasculature eliminating epistaxis derived from telangiectases. Thus, the antiangiogenic properties of proprano...Continue Reading

References

Dec 1, 1992·The Journal of Investigative Dermatology·E W AdesT J Lawley
May 15, 1989·Biochemical and Biophysical Research Communications·F PeracchiaL Mussoni
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A J van ZonneveldD J Loskutoff
Dec 1, 1965·British Journal of Pharmacology and Chemotherapy·J W BlackR G Shanks
Apr 1, 1973·Archives of Dermatology·H C Kwaan, S Silverman
Sep 22, 1998·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·C Morales-Angulo, A del Valle-Zapico
Apr 3, 2002·The EMBO Journal·Marie-José GoumansPeter ten Dijke
Sep 14, 2002·The Journal of Biological Chemistry·Tilman Sánchez-ElsnerCarmelo Bernabéu
Nov 7, 2002·In Vitro Cellular & Developmental Biology. Animal·Sally K Sommers Smith, Dennis M Smith
Sep 24, 2004·The EMBO Journal·Franck LebrinPeter ten Dijke
Apr 15, 2006·Journal of Medical Genetics·C J GallioneD A Marchuk
Aug 1, 2007·Journal of Thrombosis and Haemostasis : JTH·H R BullerP W Kamphuisen
Jun 14, 2008·The New England Journal of Medicine·Christine Léauté-LabrèzeAlain Taïeb
Apr 2, 2009·European Journal of Human Genetics : EJHG·Fatima S Govani, Claire L Shovlin
May 27, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Borhane AnnabiRichard Béliveau
Jun 3, 2009·Current Vascular Pharmacology·Roberto ZarrabeitiaLuisa-Maria Botella
Jul 28, 2009·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·R Sánchez PérezJ De la Peña de Torres
Feb 2, 2010·International Journal of Pediatric Otorhinolaryngology·A P ZimmermannB Eivazi
May 12, 2010·The British Journal of Dermatology·C H Storch, P H Hoeger
Nov 20, 2010·The FEBS Journal·Chrisostomi GialeliNikos K Karamanos
Jan 27, 2011·British Journal of Haematology·Patrizia SuppressaSabbà Carlo
Jul 22, 2011·Actas dermo-sifiliográficas·I Sánchez-CarpinteroJ C López-Gutiérrez
Nov 15, 2011·American Journal of Otolaryngology·Scott E Olitsky

❮ Previous
Next ❯

Citations

Mar 8, 2013·Drug Design, Development and Therapy·Bojko BjelakovicDusica Randjelovic
Apr 29, 2014·Vascular Pharmacology·Miguel Perez-AsoM Dolores Ivorra
Dec 24, 2013·The Journal of Dermatological Treatment·Claudia PföhlerCornelia S L Müller
Mar 27, 2015·Clinical and Experimental Dermatology·V R SimK Harman
Sep 24, 2015·Orphanet Journal of Rare Diseases·Virginia AlbiñanaLuisa María Botella
Feb 27, 2015·Frontiers in Genetics·Daniela S Ardelean, Michelle Letarte
Jan 25, 2017·Health and Quality of Life Outcomes·Roberto ZarrabeitiaJosé Antonio Parra
Dec 30, 2016·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·A ContisP Duffau
May 26, 2012·Thrombosis and Haemostasis·Georg Breier
Aug 11, 2017·Expert Opinion on Therapeutic Targets·Lidia Ruiz-LlorenteCarmelo Bernabeu
Feb 3, 2018·International Forum of Allergy & Rhinology·Ashleigh A HaldermanBradley F Marple
Oct 1, 2017·Circulation Research·Sara I CunhaMaria Grazia Lampugnani
Mar 13, 2018·F1000Research·Miguel-Angel Díaz-CastellanosLuisa-María Botella
Mar 26, 2019·The Laryngoscope·Santos Esteban-CasadoLuisa Botella Cubells
Apr 3, 2019·International Angiology : a Journal of the International Union of Angiology·Stefano PaolacciMatteo Bertelli
Oct 1, 2019·The Laryngoscope·Nadim KhoueirBenjamin Verillaud
Jun 11, 2020·Journal of Clinical Medicine·Virginia AlbiñanaLuisa María Botella
Sep 29, 2020·Laryngo- rhino- otologie·Caroline Theresa SeebauerKornelia Elisabeth Andorfer
Jul 1, 2017·Orphanet Journal of Rare Diseases·Virginia AlbiñanaLuisa María Botella
Oct 6, 2017·Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'oto-rhino-laryngologie Et De Chirurgie Cervico-faciale·Meir Mei-ZahavNeta Goldschmidt
Dec 9, 2017·Otolaryngologic Clinics of North America·Thomas KühnelVeronika Vielsmeier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

International Journal of Pediatric Otorhinolaryngology
Catherine BlanchetMichel Mondain
The New England Journal of Medicine
Christine Léauté-LabrèzeAlain Taïeb
The British Journal of Dermatology
S T TanP Leadbitter
Journal of the American Academy of Dermatology
Martine F RaphaëlJohannes M P J Breur
© 2021 Meta ULC. All rights reserved